Autoimmune Diseases

AGA Releases Expert Commentary for IBD Management During COVID-19

April 27, 2020

Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.

Long-Term Data Show Sustained Benefit of Siponimod for Secondary Progressive MS

April 22, 2020

Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.

FDA Accepts sBLA for Shorter Infusion Time with Ocrelizumab

April 20, 2020

Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.

Autoimmunity Prevalence Increasing in the United States

April 08, 2020

Autoimmunity and certain autoimmune diseases have been increasing in prevalence in the United States.

FDA OKs Ixekizumab for Pediatric Patients with Plaque Psoriasis

April 06, 2020

Officials with the FDA have granted approval to ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.

FDA Approves Ozanimod for Relapsing Multiple Sclerosis

March 27, 2020

Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.

What Pharmacists Should Know About Multiple Sclerosis

March 16, 2020

Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.

What Pharmacists Should Know About Trends in IBD Treatment

February 10, 2020

Pharmacists can play an integral role in managing patients with inflammatory bowel disease (IBD) through medication management. 

New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis

February 04, 2020

Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.

AGA Releases New Guidelines on Management of Ulcerative Colitis

January 24, 2020

Evidence-based recommendations focus on immunomodulators, biologics, and small molecules for the management of ulcerative colitis.